I am a hematologist/oncologist whose primary research interest is in leukemia, myelodysplasia, and myeloproliferative disorders. My current research focus is on immune system manipulations for therapeutic effects in patients with relapsed and refractory blood cancers.
In the clinic, I see patients with both malignant and non-malignant blood disorders.
| Martin P, Bartlett NL, Chavez JC, Reagan JL, Smith SM, LaCasce AS, Jones J, Drew J, Wu C, Mulvey E, Revuelta MV, Cerchietti L, Leonard JP. "Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL." Blood, vol. 139, no. 8, 2022, pp. 1147-1159. |
| Ollila TA, Masel RH, Reagan JL, Lu S, Rogers RD, Paiva KJ, Taher R, Burguera-Couce E, Zayac AS, Yakirevich I, Niroula R, Barth P, Olszewski AJ. "Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies." Cancer, vol. 128, no. 18, 2022, pp. 3319-3329. |
| Muthiah A, Ohnigian S, Reagan JL, Hsu A. "Thrombosis in COVID 2022: An Updated Narrative Review of Current Literature and Inpatient Management." Rhode Island medical journal (2013), vol. 105, no. 6, 2022, pp. 36-40. |
| Ollila T, Butera J, Egan P, Reagan J, Thomas A, Yakirevich I, MacKinnon K, Margolis J, McMahon J, Rosati V, Olszewski AJ. "Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study." The oncologist, vol. 27, no. 7, 2022, pp. 532-e542. |
| Vale CA, Egan PC, Ingham R, Farmakiotis D, Reagan JL. "Antibiotic use during cytarabine consolidation in acute myeloid leukemia." Annals of Hematology, vol. 100, no. 1, 2021, pp. 79-84. |
| Barth P, Giri S, Reagan JL, Olszewski AJ. "Outcomes of lenalidomide- or bortezomib-based regimens in older patients with plasma cell myeloma." American Journal of Hematology, vol. 96, no. 1, 2021, pp. 14-22. |
| Di, Mengyang, Panagiotou, Orestis A., Reagan, John L., Niroula, Rabin, Olszewski, Adam J. "Adjuvant chemotherapy administration and survival outcomes of lymphoma survivors with common solid tumors: a population-based study†." Leukemia & Lymphoma, vol. 61, no. 14, 2020, pp. 1-9. |
| Hsu A, Matera R, Vieira K, Reagan JL, Farmakiotis D. "Antifungal prophylaxis during 7 + 3 induction chemotherapy for acute myeloid leukemia is associated with improved survival, in a setting with low incidence of invasive mold infections." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, vol. 29, no. 2, 2020, pp. 707-712. |
| Sahin I, Reagan JL. "Asciminib in Relapsed Chronic Myeloid Leukemia." New England Journal of Medicine, vol. 382, no. 14, 2020, pp. 1378-1379. |
| Moore JW, Pelcovits A, Reagan JL. "Azacitidine and Venetoclax in AML." New England Journal of Medicine, vol. 383, no. 21, 2020, pp. 2088. |
| Zayac AS, Hilliard RW, Olszewski AJ, Pelcovits A, Reagan JL, Hsu A, Riley D, Austin M, Ollila TA. "Enforcing the "4T": An In-Line Calculator for HIT Antibody Ordering in the Electronic Medical Record." Rhode Island medical journal (2013), vol. 103, no. 8, 2020, pp. 78-83. |
| Cheng Y, Pereira M, Raukar NP, Reagan JL, Quesenberry M, Goldberg L, Borgovan T, LaFrance Jr WC, Dooner M, Deregibus M, Camussi G, Ramratnam B, Quesenberry P. "Inflammation-related gene expression profiles of salivary extracellular vesicles in patients with head trauma." Neural regeneration research, vol. 15, no. 4, 2020, pp. 676-681. |
| Hsu A, Liu Y, Zayac AS, Olszewski AJ, Reagan JL. "Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia." Thrombosis research, vol. 196, 2020, pp. 375-378. |
| Hsu A, Mistry H, Lala N, Reagan JL. "Preliminary findings regarding the use of direct oral anticoagulants in cerebral venous thrombosis." Clinical Neurology and Neurosurgery, vol. 198, 2020, pp. 106204. |
| Castillo JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, Cartron G, Ninkovic S, Cwynarski K, Dierickx D, Tousseyn T, Lansigan F, Linnik Y, Mogollon R, Navarro JT, Olszewski AJ, Reagan JL, Fedele P, Gilbertson M, Grigoriadis G, Bibas M. "Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma." British Journal of Haematology, vol. 184, no. 4, 2019, pp. 679-682. |
| Ollila TA, Reagan JL, Olszewski AJ. "Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base." Leukemia & Lymphoma, vol. 60, no. 14, 2019, pp. 3426-3433. |
| Olszewski AJ, Chorzalska AD, Kim AS, Quesenberry PJ, Lopresti ML, Fenton MA, Reagan JL, Butera JN, Sahin I, Hamel C, Robison J, Petersen M, Dubielecka PM. "Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy." British Journal of Haematology, vol. 186, no. 3, 2019, pp. e31-e35. |
| Austin M, Quesenberry PJ, Ventetuolo CE, Liang O, Reagan JL. "Prevalence and Effect on Survival of Pulmonary Hypertension in Myelofibrosis." Clinical lymphoma, myeloma & leukemia, vol. 19, no. 9, 2019, pp. 593-597. |
| Chorzalska A, Morgan J, Ahsan N, Treaba DO, Olszewski AJ, Petersen M, Kingston N, Cheng Y, Lombardo K, Schorl C, Yu X, Zini R, Pacilli A, Tepper A, Coburn J, Hryniewicz-Jankowska A, Zhao TC, Oancea E, Reagan JL, Liang O, Kotula L, Quesenberry PJ, Gruppuso PA, Manfredini R, Vannucchi AM, Dubielecka PM. "Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis." Blood, vol. 132, no. 19, 2018, pp. 2053-2066. |
| Pando A, Reagan JL, Quesenberry P, Fast LD. "Extracellular vesicles in leukemia." Leukemia Research, vol. 64, 2018, pp. 52-60. |
| Pando, Alejandro, Reagan, John L., Nevola, Martha, Fast, Loren D. "Induction of anti-leukemic responses by stimulation of leukemic CD3+ cells with allogeneic stimulator cells." Experimental Hematology & Oncology, vol. 7, no. 1, 2018, pp. 25. |
| Ollila TA, Olszewski AJ, Butera JN, Quesenberry MI, Quesenberry PJ, Reagan JL. "Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease." Clinical lymphoma, myeloma & leukemia, vol. 18, no. 3, 2018, pp. 204-209. |
| Chorzalska A, Ahsan N, Rao RSP, Roder K, Yu X, Morgan J, Tepper A, Hines S, Zhang P, Treaba DO, Zhao TC, Olszewski AJ, Reagan JL, Liang O, Gruppuso PA, Dubielecka PM. "Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia." Molecular oncology, vol. 12, no. 5, 2018, pp. 630-647. |
| Le A, Farmakiotis D, Reagan JL. "Pruritic Rash in a Patient with Hodgkin's Lymphoma." Cureus, vol. 10, no. 4, 2018, pp. e2450. |
| Sahin I, Reagan JL, Niroula R, Sweeney JD. "Refractoriness to red blood cell transfusion therapy due to hypersplenism." Transfusion, vol. 58, no. 11, 2018, pp. 2513-2516. |
| Barth P, Vale C, Chambers AB, Reagan JL. "The next generation of therapy for multiple myeloma: a review of ongoing clinical trials utilizing ClinicalTrials.gov." Future oncology (London, England), vol. 14, no. 19, 2018, pp. 1965-1976. |
| Egan, Pamela C, Reagan, John L. "The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody–drug conjugate for the treatment of newly diagnosed acute myeloid leukemia." OncoTargets and Therapy, vol. Volume 11, 2018, pp. 8265-8272. |
| "Dysuria in a Patient With AIDS and Lymphoma." Clinical Infectious Diseases, vol. 65, no. 5, 2017, pp. 867-867. |
| Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM, Gozzetti A, Gustine JN, Hajek R, Hungria V, Jarkovsky J, Jayabalan D, Laubach JP, Lewicka B, Maisnar V, Manasanch EE, Moreau P, Morgan EA, Nahi H, Niesvizky R, Paba-Prada C, Pika T, Pour L, Reagan JL, Richardson PG, Shah J, Spicka I, Vij R, Waszczuk-Gajda A, Gertz MA. "IgM myeloma: A multicenter retrospective study of 134 patients." American Journal of Hematology, vol. 92, no. 8, 2017, pp. 746-751. |
| Rafelson WM, Reagan JL, Fast LD, Lim SH. "Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?." Leukemia & Lymphoma, vol. 58, no. 11, 2017, pp. 1-9. |
| Olszewski AJ, Reagan JL, Castillo JJ. "Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas." American Journal of Hematology, vol. 93, no. 1, 2017, pp. E1-E3. |
| Shallis RM, Rome RS, Reagan JL. "Mechanisms of Hypercalcemia in Non-Hodgkin Lymphoma and Associated Outcomes: A Retrospective Review." Clinical lymphoma, myeloma & leukemia, 2017. |
| Black RC Jr, Reagan J, Taliano R, Farmakiotis D. "Rhomboid glossitis in disseminated CMV infection." IDCases, vol. 8, 2017, pp. 42-44. |
| Mantripragada KC, Rizk SF, Reagan JL, LeGolvan M. "Acquired Syphilis With Anemia and Leukoerythroblastic Reaction: A Case Report." Annals of Internal Medicine, vol. 165, no. 3, 2016, pp. 226-7. |
| Mantripragada KC, Olszewski AJ, Schumacher A, Perez K, Birnbaum A, Reagan JL, Mega A, Khurshid H, Bartley C, Lombardo A, Rossiter R, Papa A, Bakalarski P, Safran H. "Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program." Journal of Oncology Practice, vol. 12, no. 4, 2016, pp. e396-404. |
| Foderaro, A. E., Reagan, J. L. "Hodgkin lymphoma mimicking lung abscess." Blood, vol. 128, no. 25, 2016, pp. 3011-3011. |
| Foderaro AE, Reagan JL. "Hodgkin lymphoma mimicking lung abscess." Blood, vol. 128, no. 25, 2016, pp. 3011. |
| Castillo, Jorge J., Reagan, John L., Sikov, William M., Winer, Eric S. "Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma." British Journal of Haematology, vol. 169, no. 3, 2015, pp. 352-355. |
| Reagan JL, Fast LD, Nevola M, Mantripragada K, Mulder A, Claas FH, Rosati K, Schumacher A, Safran H, Young CT, Quesenberry MI, Winer ES, Butera JN, Quesenberry PJ. "Nonengraftment donor lymphocyte infusions for refractory acute myeloid leukemia." Blood cancer journal, vol. 5, 2015, pp. e371. |
| Reagan, John L., Sullivan, Matthew R., Winer, Eric S., Lansigan, Frederick, Cardin, Michael S., Castillo, Jorge J. "Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study." Leukemia Research, vol. 39, no. 8, 2015, pp. 812-7. |
| Reagan JL. "Adoptive immunotherapy for myeloid malignancies." Leukemia Supp, vol. 3, no. Suppl 1, 2014, pp. S21-2. |
| Mantripragada K, Reagan JL, Quesenberry PJ, Fast LD. "Advances in cellular therapy for the treatment of leukemia." Discovery medicine, vol. 17, no. 91, 2014, pp. 15-24. |
| Reagan JL, Ingham RR 2nd, Dalia S, Butera JN, Sweeney JD. "Differences in the clinical course of heparin induced thrombocytopenia before and after the availability of HIT IgG class testing." Thrombosis research, vol. 134, no. 1, 2014, pp. 90-2. |
| Chorzalska A, Salloum I, Shafqat H, Khan S, Marjon P, Treaba D, Schorl C, Morgan J, Bryke CR, Falanga V, Zhao TC, Reagan J, Winer E, Olszewski AJ, Al-Homsi AS, Kouttab N, Dubielecka PM. "Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia." Leukemia, vol. 28, no. 11, 2014, pp. 2165-77. |
| Castillo JJ, Ingham RR, Reagan JL, Furman M, Dalia S, Mitri J. "Obesity is associated with increased relative risk of diffuse large B-cell lymphoma: a meta-analysis of observational studies." Clinical lymphoma, myeloma & leukemia, vol. 14, no. 2, 2014, pp. 122-30. |
| Reagan JL, Castillo JJ. "Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia." Future oncology (London, England), vol. 10, no. 7, 2014, pp. 1147-55. |
| Gavini A, Reagan JL, Winer ES, Castillo JJ. "Primary refractory Hodgkin lymphoma: limited options and poor survival--but not always." American Journal of Hematology, vol. 89, no. 8, 2014, pp. 853-7. |
| Castillo JJ, Reagan JL, Bishop KD, Apor E. "Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies." British Journal of Haematology, vol. 165, no. 3, 2014, pp. 300-15. |
| Reagan JL, Fast LD, Safran H, Nevola M, Winer ES, Castillo JJ, Butera JN, Quesenberry MI, Young CT, Quesenberry PJ. "Cellular immunotherapy for refractory hematological malignancies." Journal of Translational Medicine, vol. 11, 2013, pp. 150. |
| Pham A, Reagan JL, Castillo JJ. "Multiple myeloma-induced hyperammonemic encephalopathy: an entity associated with high in-patient mortality." Leukemia Research, vol. 37, no. 10, 2013, pp. 1229-32. |
| Castillo JJ, Mull N, Reagan JL, Nemr S, Mitri J. "Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies." Blood, vol. 119, no. 21, 2012, pp. 4845-50. |
| Reagan JL, Fast LD, Winer ES, Safran H, Butera JN, Quesenberry PJ. "Nonengraftment haploidentical cellular therapy for hematologic malignancies." Advances in hematology, vol. 2012, 2012, pp. 784213. |
| Castillo JJ, Reagan JL, Ingham RR, Furman M, Dalia S, Merhi B, Nemr S, Zarrabi A, Mitri J. "Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies." Leukemia Research, vol. 36, no. 7, 2012, pp. 868-75. |
| Reagan JL, Castillo JJ. "Why is my patient neutropenic?." Hematology/oncology clinics of North America, vol. 26, no. 2, 2012, pp. 253-66, vii. |
| Del Tatto M, Ng T, Aliotta JM, Colvin GA, Dooner MS, Berz D, Dooner GJ, Papa EF, Hixson DC, Ramratnam B, Aswad BI, Sears EH, Reagan J, Quesenberry PJ. "Marrow cell genetic phenotype change induced by human lung cancer cells." Experimental hematology, vol. 39, no. 11, 2011, pp. 1072-80. |
| Reagan JL, Castillo JJ. "Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia." Expert review of anticancer therapy, vol. 11, no. 2, 2011, pp. 151-60. |
| Reagan JL, Rosmarin A, Butera JN, Nadeem A, Schiffman FJ, Sikov WM, Winer E, Mega AE. "Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL." Cancer chemotherapy and pharmacology, vol. 68, no. 4, 2011, pp. 1075-80. |
| Castillo JJ, Reagan JL. "Plasmablastic lymphoma: a systematic review." TheScientificWorldJournal, vol. 11, 2011, pp. 687-96. |
| Yuan J, Latouche JB, Reagan JL, Heller G, Riviere I, Sadelain M, Young JW. "Langerhans cells derived from genetically modified human CD34+ hemopoietic progenitors are more potent than peptide-pulsed Langerhans cells for inducing antigen-specific CD8+ cytolytic T lymphocyte responses." The Journal of Immunology, vol. 174, no. 2, 2005, pp. 758-66. |
| Sénéchal B, Boruchov AM, Reagan JL, Hart DN, Young JW. "Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83." Blood, vol. 103, no. 11, 2004, pp. 4207-15. |
| Ratzinger G, Baggers J, de Cos MA, Yuan J, Dao T, Reagan JL, Münz C, Heller G, Young JW. "Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells." The Journal of Immunology, vol. 173, no. 4, 2004, pp. 2780-91. |
| Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW. "Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation." Blood, vol. 101, no. 4, 2003, pp. 1422-9. |
Leukemia and Lymphoma Society Special Fellow in Clinical Research Career Development Award, $195,0000, 7/1/2013
Center of Biomedical Research Excellence at Rhode Island Hospital, $50,000, 7/1/2013
Rhode Island Foundation Biomedical Research Grant, $25,000
Center of Biomedical Research Excellence at Rhode Island Hospital, $50,000, 7/1/2017
| Year | Degree | Institution |
|---|---|---|
| 2010 | MD | Upstate Medical University |
| 2000 | BA | Hamilton College |
| Name | Title |
|---|---|
| Butera, James | Clinical Associate Professor of Medicine |
| Dubielecka-Szczerba, Patrycja | Associate Professor of Medicine |
| Fast, Loren | Associate Professor Emeritus of Medicine |
| Liang, Olin | Associate Professor of Medicine (Research) |
| Olszewski, Adam | Associate Professor of Medicine |
| Quesenberry, Matthew | Assistant Professor of Medicine, Clinician Educator |
| Quesenberry, Peter | Paul Calabresi, M.D. Professor of Oncology, Professor of Medicine |
| Safran, Howard | Professor of Medicine |
| Young, Carolyn | Adjunct Assistant Professor of Pathology and Laboratory Medicine |
American Society of Hematology (ASH)
American Society of Clinical Oncology (ASCO)
American Association of Cancer Research (AACR)
American Society for Transplantation and Cellular Therapy (ASTCT)
